AstraZeneca strengthens COPD treatment pathways
AstraZeneca India, a science-led biopharmaceutical company, is advancing its commitment to chronic respiratory care by extending…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
COPD
Real-world data backs anti-IL-5 use in COPD with comorbid asthma
GlobalData’s latest analysis highlights the results of a retrospective study from Ghent University Hospital based on Belgian…
Lupin collaborates with Honeywell, plans for HFO technology in Inhalers
Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas…
GSK’s Nucala highlights IL-5 inhibition in reducing COPD exacerbations in eosinophilic patients:…
In both groups, Nucala significantly lowered the rate of exacerbations requiring emergency department (ED) visits or…
COPD diagnosed prevalent cases across 7MM to reach 38.02 million in 2033, forecasts GlobalData
COPD diagnosed prevalent cases in 7MM set to increase, with significant age and regional variations, according to GlobalData
EMA approval of Sanofi/Regeneron’s Dupixent fills biologic gap in COPD: GlobalData
Dupixent shows promise for COPD, new treatment option reduces flare - ups and improves breathing
AstraZeneca receives CDSCO approval to market its inhalation aerosol
The pressurised metered dose inhaler is recommended for the treatment and maintenance of patients with Chronic Obstructive…
Lupin partners with Cost Plus Drugs, COPD Foundation
The collaboration seeks to expand availability of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, to COPD patients in the US…
Lupin receives approval from TGA Australia for Tiotropium dry powder
The product will be manufactured at Lupin’s Pithampur facility in India
Lupin signs MoU with Maha Govt to combat cardiovascular diseases and COPD
Collaboration to enhance healthcare services, ensure timely diagnosis, and improve accessibility of healthcare services